465 Studies Now Enrolling
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study toEvaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation ofPancreatic Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus
Trial Net JAKPOT Type 1 Diabetes (T1D)
| Sponsor: | National Institute of Diabetes and Digestive and Kidney Diseases NIDDK |
| Enrolling: | Male and Female Patients |
| Study Length: | 2 Years |
| IRB Number: | AAAU7453 |
| U.S. Govt. ID: | NCT05743244 |
| Contact: | Kaisha Mofford: 212-851-5512 / km3870@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is testing two different Janus kinase (JAK) inhibitors, Abrocitinib and Ritlecitinib, to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D). Researchers believe JAK inhibitors may be able to calm the immune system's attack on insulin producing beta cells in the pancreas.
